MedTrace Logo

Angiotensin-(1-7) and Energy Expenditure in Human Obesity

NCT03777215 · Status: ACTIVE_NOT_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-09-19

No results posted yet for this study

Summary

The objective of this study is to better define the role of the hormone angiotensin-(1-7) in energy balance. We will test the overall hypothesis that angiotensin-(1-7) increases resting energy expenditure and promotes markers of heat production (thermogenesis) in white adipose tissue in human obesity.

Conditions

Interventions

DRUG

Angiotensin-(1-7)

This is a biologically active beneficial hormone of the renin-angiotensin system.

DRUG

Saline

Saline will be used as the placebo comparator.

Sponsors & Collaborators

  • Amy Arnold

    lead OTHER

Principal Investigators

  • Amy C Arnold, PhD · Pennsylvania State University College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-26
Primary Completion
2026-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03777215 on ClinicalTrials.gov